人工智能的飞速发展为生物学研究带来了深远影响，其中，AlphaFold2在蛋白质结构预测领域引发了革命性的突破。本文评估了AlphaFold2对GPCR结构预测的可靠性，发现其虽能准确捕捉GPCR整体骨架的主要特征，但在胞外域与跨膜域的组装、配体结合口袋的形状以及信号传导界面的构象等方面，与实验解析的高分辨率结构存在显著差异。这些差异限制了其在GPCR功能研究和基于结构的药物设计中的应用能力。因此 ...

本文聚焦传统药物与 GPCR，介绍相关研究进展及平台策略，助力新药研发。 传统药物与 GPCR 研究背景 传统药物源自草药、药用动物和真菌，在全球使用历史悠久。2023 年 5 月第 76 届世界卫生大会制定了 2025 - 2034 年世界卫生组织全球传统医学战略，旨在推动传统 ...

研究人员探索 GPR52 的翻译后修饰（PTMs），发现 N 端 N 糖基化 和磷酸化影响其信号偏向与功能。 尽管 G 蛋白偶联受体（GPCR）生物学最近取得了进展，但翻译后修饰（PTMs）对 GPCR 激活、信号传导和功能的调节在很大程度上仍未被探索。在对 GPR52（一种具有极高 ...

Maxion Therapeutics是一家蛋白质疗法研究服务商，专注于蛋白质疗法，提供长效、安全、有效的药物，用于治疗以前无法治疗的离子通道和gpcr驱动的疾病。近日，Maxion Therapeutics获得7200万美元A轮融资，General Catalyst Partners、British Patient Capital、Solasta Ventures、Lilly Ventures、 ...

Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...

Cambridge, UK-based biotech start-up Maxion Therapeutics, which is developing antibody-based KnotBody drugs for ion channel- ...

Maxion Therapeutics Ltd. has raised $72 million (£58 million) in a series A financing to support its development of antibody-based Knotbody drugs for ion channel- and G protein-coupled receptor (GPCR) ...

Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Structure ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(NASDAQ:GPCR – Free Report) by 29.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,228 shares of the company’s stock ...